{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T06:15:37Z","timestamp":1784614537085,"version":"3.55.0"},"reference-count":26,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:00:00Z","timestamp":1758585600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["eJHaem"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>A novel therapy for heavily pretreated triple\u2010class\u2013exposed multiple myeloma (TCE MM) is B\u2010cell maturation antigen (BCMA)\u2010targeted immunotherapy. While the number of TCE+BCMA\u2010exposed patients is growing, real\u2010world data for this group are limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We present real\u2010world data from patients with TCE+BCMA\u2010exposed MM who initiated a subsequent line of therapy (LOT) using a US\u2010based claims database, Komodo's Healthcare Map.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We identified 656 TCE+BCMA\u2010exposed patients; mean age was 66.5\u00a0years. Time from MM diagnosis to index was 5.4\u00a0years; mean number of prior LOTs was 5.9. The most prevalent prior therapy received within each drug class was daratumumab (98.5%), pomalidomide (86.0%), carfilzomib (85.8%) and belantamab mafodotin (74.5%). A total of 137 different subsequent treatment regimens were observed following TCE+BCMA exposure; the most common regimen was teclistamab (10.4%). The top three targeted agents within the subsequent regimen were carfilzomib (20.2%), pomalidomide (20.1%) and bortezomib (16.6%). Among this TCE+BCMA\u2010exposed population who received subsequent treatment, the median time to next treatment or death was 6.8 (95% CI, 6.1\u20137.5) months; time to treatment discontinuation or death was 3.5 (95% CI, 3.2\u20133.7) months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This first real\u2010world analysis of patients with heavily pretreated TCE+BCMA\u2010exposed MM shows poor clinical outcomes, frequent therapy retreatment and no standard\u2010of\u2010care, highlighting the need for novel treatments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Trial Registration<\/jats:title>\n                    <jats:p>The authors have confirmed clinical trial registration is not needed for this submission.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/jha2.70145","type":"journal-article","created":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T12:54:57Z","timestamp":1758632097000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Real\u2010World Treatment Patterns and Clinical Outcomes Among Patients With Triple\u2010Class\u2013Exposed and BCMA\u2010Exposed Multiple Myeloma Within the United States"],"prefix":"10.1002","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1584-1067","authenticated-orcid":false,"given":"Hira S.","family":"Mian","sequence":"first","affiliation":[{"name":"Department of Oncology McMaster University  Hamilton Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer S.","family":"Harper","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson  Titusville New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoa H.","family":"Le","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson  Horsham Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex Z.","family":"Fu","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson  Titusville New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saurabh","family":"Patel","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson  Horsham Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinke","family":"Zhang","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson  Horsham Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Fonseca","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology Mayo Clinic  Phoenix Arizona USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,9,23]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph16030415"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1177\/10781552231154809"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14213"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(23)01875-X"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-186616"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2024.02.006"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1177\/10781552211073517"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30788-0"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33809"},{"key":"e_1_2_11_11_1","unstructured":"\u201cGSK Provides an Update on Blenrep (belantamab mafodotin\u2010blmf) US Marketing Authorisation\u201d GSK accessed 17 December 2024 https:\/\/www.gsk.com\/en\u2010gb\/media\/press\u2010releases\/gsk\u2010provides\u2010update\u2010on\u2010blenrep\u2010us\u2010marketing\u2010authorisation\/."},{"key":"e_1_2_11_12_1","volume-title":"TECVAYLI\u00ae (teclistamab\u2010cqyv) Injection [package insert]","year":"2022"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2203478"},{"key":"e_1_2_11_14_1","volume-title":"ELREXFIO\u2122 (elranatamab\u2010bcmm) Injection, for Subcutaneous Use [package insert]","year":"2023"},{"key":"e_1_2_11_15_1","volume-title":"ABECMA\u00ae (idecabtagene vicleucel), Suspension for Intravenous Infusion [package insert]","year":"2024"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024850"},{"key":"e_1_2_11_17_1","volume-title":"CARVYKTI\u00ae (ciltacabtagene autoleucel) Suspension for Intravenous Infusion [package insert]","year":"2024"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00933-8"},{"key":"e_1_2_11_19_1","unstructured":"\u201cKomodo Health \u201dKomodo Health Inc. accessed 6 December 2024 https:\/\/www.komodohealth.com\/."},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40487-022-00198-0"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-188591"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40487-024-00291-6"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-173661"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00886-8"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19505"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-024-02404-6"},{"key":"e_1_2_11_27_1","unstructured":"\u201cAbout Provisional Mortality Statistics 2018 Through Last Week \u201dCenters for Disease Control and Prevention accessed 18 March 2024 http:\/\/wonder.cdc.gov\/mcd\u2010icd10\u2010provisional.html."}],"container-title":["eJHaem"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jha2.70145","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T10:53:35Z","timestamp":1761389615000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jha2.70145"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,23]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1002\/jha2.70145"],"URL":"https:\/\/doi.org\/10.1002\/jha2.70145","archive":["Portico"],"relation":{},"ISSN":["2688-6146","2688-6146"],"issn-type":[{"value":"2688-6146","type":"print"},{"value":"2688-6146","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,23]]},"assertion":[{"value":"2025-08-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70145"}}